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Abstract 
Introduction  
The use of aptamers, antisense technology and RNA interference has allowed nucleic 
acids to be considered promising alternatives to classical drugs. However, nucleic acids 
face several obstacles and pitfalls in the creation of effective nucleic acid drugs. The 
development of these approaches has increased the pipeline toward clinical trials. 
Areas covered 
This review covers research and patent literature of the last three years focused on the 
development of safe and effective non-viral drug delivery systems for the treatment of 
diseases such as cancer or genetic disorders by using oligonucleotides. 
Expert opinion 
The therapeutic applications of oligonucleotides have undergone multiple obstacles 
especially in biodistribution and cellular internalization. Cationic lipids are the most 
used vehicles for the preparation of novel formulations. Combinatorial libraries of these 
compounds and the use of solid lipid nanoparticles carrying these synthetic cationic 
lipids, cholesterol and polyethyleneglycol have emerged to enhance cellular uptake and 
biocompatibility of nucleic acids. Besides this extensive use, synthesis of 
oligonucleotide covalently linked to lipids has also emerged as a promising alternative 
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to formulations. The use of peptides alone or in combination with lipids is also an 
expanding field for oligonucleotide delivery. Polymeric platforms are also good 
candidates as they showed improved cellular uptake, biodegradability, biocompatibility, 
and the possibility to incorporate several components such as ligands for receptor-
mediated endocytosis and molecules to facilitate endosomal escape. Finally, 
nanomaterials may also play an important role in the future. The last developments 
showed improved in vivo efficacy, thus gaining a foothold in therapeutics. 
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1. Introduction 
The search of novel drugs in medicinal chemistry is based on the use of small molecules 
derived from the screening thousands of compounds along with computational studies 
that directly interact with target molecules, mainly proteins.  
Nucleic acids, in contrast to conventional small drugs, are macromolecules that target 
specifically messenger RNAs (mRNAs) inhibiting the expression of a known gene 
sequence. This mode of action, that allows the specific inhibition of a target protein, 
covers a range of biomedical applications that are not treatable with current drugs [1].  
Oligonucleotides face multiple obstacles in order to be considered clinically acceptable 
therapeutic drugs. They are susceptible to degradation in the presence of nucleases and, 
because of their size and charge, oligonucleotides do not cross cell membranes by 
passive diffusion. Chemical biology of nucleic acids has accelerated the process of 
discovery of modified nucleic acids with an enhanced stability hence protecting them 
from degradation. Furthermore, these chemical modifications have also allowed the 
synthesis of novel nucleic acids with more drug-like properties, target affinity and 
specificity without losing biologic activities of natural nucleic acids [2].  
According to Figure 1, we can find at least three potential sites in order to modify 
chemically oligonucleotides: (a) the sugar ring, (b) the phosphate backbone and (c) the 
nucleobases. Chemical modifications on the sugar ring affect the stability of the 
DNA:RNA duplex and therefore improving, in most of the cases, protein binding and 
resistance to degradation in serum. These 2’-modifications mainly comprise 2’-fluoro, 
2’-O-methyl, 2’-O-methoxyethyl substituents and bicyclic sugars locked nucleic acids 
(LNAs), which have the effect to fix the sugar conformations hence increasing the 
stability of duplexes.  
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Modifications carried out directly on the phosphate group comprise phosphorothioate 
(PS) backbones, which is the most common modification in antisense oligonucleotides 
(ASOs) and siRNAs. Modified ASOs and siRNAs containing PS moieties have shown 
better stability profiles in serum facilitating intravenous and subcutaneous 
administrations. In a more radical change, the ribose phosphate backbone has been 
replaced with morpholino (PMO) moieties, a six-membered ring that has been 
successfully introduced into antisense oligonucleotides, showing low toxicities and 
promising activities. Peptide nucleic acids (PNAs) represent other kind of variation 
comprising the introduction of (2-aminoethyl)-glycine peptide backbones and replacing 
the corresponding ribose or deoxyribose rings giving strong interactions with RNA 
molecules. Because PNA are uncharged and have been shown excellent nuclease-
resistant molecules, they have been mainly evaluated in many antisense studies [3]. 
Considerable progresses made by researchers to boost drug-like properties of nucleic 
acids have allowed the launch of multiple clinical trials [4] for several ASOs and 
siRNAs (Table 1). To date, there are only a few nucleic acid-based drugs approved by 
the FDA: Macugen, a RNA aptamer [5] designed for the treatment of age-related 
macular degeneration; Mipomersen [6], a fully synthetic antisense oligonucleotide 
against hypercholesterolemia and Vitravene, an antisense oligonucleotide drug to treat 
cytomegalovirus retinitis in AIDS patients was launched in 1998 [7]. However, despite 
the increased number of potentially therapeutic nucleic acids, there are only few 
examples in which non-viral delivery agents have been employed. For instance, the use 
of either transferrin receptor-targeted nanoparticles (CALAA-01), cationic liposome-
based strategies (ALN-TTR, ALN-PCS02, Atu027, TKM-080301) or the use of 
polymeric nanoparticles (CRLX-101) are in progress. The rest of the modified siRNAs 
and ASOs that are under active investigation are directly administered in their natural 
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unmodified form without using any delivery system, being ocular, electroporation, 
parenteral, intramuscular or systemic the most preferred administration routes.  
The ability of oligonucleotides to cross cell membranes is very poor. The use of viral 
carriers, like retrovirus or adeno-associated virus (AAV) increases the transfection 
efficiencies of nucleic acids. However, several concerns about the immunogenicity and 
possible recombination of oncogenes have been expressed [8]. It is for this reason that 
non-viral carriers have emerged in the last years as safer alternatives inducing less 
toxicity and immunogenicity although their transfection efficiencies are lower compared 
to viral vectors [9]. The development of biocompatible materials (Figure 2) such as 
cationic lipids [10], liposomes [11], stable nucleic acid lipid particles (SNALPs) [12], 
polymers [13] or cell-penetrating peptides [14] has allowed nucleic acids to bind to non-
viral carriers taking advantage of the electrostatic interactions. 
The development of covalent strategies has also allowed the synthesis of more stable 
conjugates containing lipids [15], polymers [16] or dendrimers [17] with 
oligonucleotides. The use of neutral lipids like cholesterol is one of the preferred 
strategies for the chemical modification of nucleic acids. In particular, cholesterol-
siRNA constructs have considerably improved the cellular uptake properties of siRNA 
molecules hence facilitating their intravenous administration for silencing ApoB 
expression with good efficiencies [18]. Nonetheless, despite these promising results, the 
use of covalent strategies remains scarcely exploited compared to electrostatic 
formulations, which are being used in the majority of clinical trials in both antisense and 
RNA interference therapies.  
2. Strategies using short nucleic acids as drugs 
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2.1 Antisense technology and RNA interference 
Antisense technology and RNA interference (RNAi) mechanisms are the major 
processes to control gene expression. In both cases, the expression of disease-causing 
proteins is down-regulated at the level of mRNA. In the case of antisense technology 
(Figure 3A), single-stranded ASO molecules are able to interact with target mRNA 
through Watson-Crick base-pair interactions within hybridization-accessible sites. 
Depending on the design and the chemistry, the corresponding ASO:RNA hydrid may 
result in degradation by the action of RNAseH endonuclease that hydrolyzes the duplex, 
therefore inhibiting the synthesis of proteins. This particular strategy also includes 
miRNA-based constructs such as antagomirs, locked nucleic acids (LNA) anti-miR, 
microRNA sponges and miR-masks that have shown good results in gene inhibition. 
RNAi mechanism (Figure 3B) is the other approach to control the gene activity. This 
mechanism occurs in the cytoplasm and is based on the recognition of double-stranded 
small interference RNA (siRNA) by a multi-protein complex called RNA-induced 
silencing complex (RISC). First, long double-stranded RNAs (dsRNA) are cleaved by 
the action of the RNAse endonuclease Dicer producing siRNAs. After siRNAs are 
loaded into the RISC complex, Argonaute-2 protein (Ago-2), which is one of the 
components of RISC, cleaves and releases the passenger strand of siRNA, leading to an 
activated form of RISC that contains a guide strand of RNA. The guide strand binds to 
target mRNA by intermolecular base pairing and mRNA is cleaved thereby inhibiting 
protein synthesis. 
Synthetic miRNA mimics to restore tumor suppressor miRNA-expressionBesides 
cellular uptake limitations, there are two additional hurdles to overcome in RNAi. 
Synthetic siRNAs in mammalian cells could interfere with the effect produced by 
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micro-RNAs (miRNAs), which control the efficiency of mRNA translations giving 
undesirable off-target effects [19]. Moreover, siRNAs can activate the immune response 
by activating Toll-like receptors leading to unwanted side effects.  
2.2 Aptamers 
Aptamers are nucleic acids with high affinity to a particular protein. These molecules 
are initially selected by means of PCR-based techniques, starting from random libraries 
of short nucleotide segments (SELEX). Interesting applications of aptamers in the 
biosensing field are related to the analysis of chemical or biological pollutants but also 
they can also be used as potential drugs [20]. The first aptamer-based drug was 
approved by the FDA. Pegaptanib or macugen binds the isoform of VEGF165 and 
inhibits its interaction with the VEGF receptor [21] being used in the treatment of age-
related macular degeneration. 
 
3. Evaluation of patents  
Patent literature in this review is divided into several areas depending on the nature of 
the compounds used for enhancing cellular uptake. 
 
3.1 Formulations containing cationic lipids 
Cationic lipids constitute the main non-viral approach to deliver nucleic acids inside 
cells. Although there are some limitations associated to their use, such as low 
transfection efficiencies, toxicity and stability in the presence of serum [22], to date, the 
design and synthesis of novel cationic lipid libraries and lipid-like molecules has 
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prompted promising improvements in the delivery of siRNA and ASO molecules in 
both in vitro and in vivo experiments [23].  
Solid lipid nanoparticles (SLNP) have emerged as an alternative to liposomes. These 
drug delivery vehicles combine the advantages of lipid emulsions and polymeric 
nanoparticles and overcome some issues like the stability of the particles in vivo [24]. 
They are composed of cationic lipids to provide higher efficiency in neutralizing the 
negative charge of nucleic acids by forming tighter complexes; cationic or fusogenic 
lipids and, finally, hydrophilic molecules such as polyethylene glycol (PEG) 
derivatives, which generally improve the plasma stability and biodistribution by altering 
the surface properties of SLNPs.  
The therapeutic effects of some SLNPs in RNAi or antisense technology have been 
reported in multiple in vivo experiments and clinical trials for hypercholesterolemia, 
transthyretin (TTR), solid tumors or cancer treatments (see Table 1) becoming systemic 
administrations as the most preferred application for these delivery platforms [25, 26].  
PEGylated lipids, also known as shielding lipids, are one of the most usual components 
of SLNPs along with cationic lipids. In general, the role of PEGylated lipids in 
formulations is mainly based on regulating fusogenicity, shielding surface charges, 
reducing the particle size and avoiding aggregation during storage [27]. Furthermore, 
the presence of these shielding lipids in SLNPs normally causes better tolerability in 
vivo hence improving the pharmacokinetic profiles of the particles. In order to increase 
the efficacy of such SLNPs, some groups have optimized the chemical space by 
synthesizing combinatorial libraries of novel PEGylated and cationic lipids evaluating 
their efficiencies in both in vitro and in vivo studies. In particular, a series of novel 
PEGylated derivatives have been synthesized and combined with various synthetic 
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cationic lipids to form the SLNPs formulations. For instance, Alnylam Pharmaceuticals 
[28, 29] and Abbott Laboratories [30] published several patent applications in which 
synthetic approaches to obtain a variety of shielding lipids were described. Some of 
them are displayed in Figure 4A. The strategy followed by Alnylam consisted of fixing 
the hydrophobic part with a long hydrocarbonated alkyl chain and subsequently varying 
the hydrophilic part by introducing several series of ethylene glycol derivatives (PEG-
C-DMSO, PEG-C-DMSA, 3 and 4). In the case of the method described by Abbott 
Laboratories, the hydrophilic part was maintained fixed varying the length of 
hydrocarbonated alkyl chains (lipid-PEG derivatives 5 and 6). In both cases, these lipid-
based particles were prepared by using preformed vesicle methods. A first screening 
containing PEG-C-DMSA in the formulation revealed better silencing activities than 
using PEG-C-DSMO in subcutaneous Hep3B-luc tumors in mice (58 versus 30%, 
respectively). The optimal formulations containing PEG-C-DMSA were also studied in 
vitro and in vivo in order to silence murine clotting factor VII mRNA, which is a 
prominent protein in the coagulation cascade [29]. The preparation of several SLNPs 
containing PEGylated lipids 5 and 6 along with other PEGylated lipids, such as PEG-
Chol, was carried out to determine the transfection efficiency both in vitro and in 
several tumor models of siRNAs targeting the expression of luciferase [30].  
Cationic lipids are the other major components of SLNPs. Several companies have 
carried out an exhaustive study to elucidate the structure-activity relationship (SAR) of 
these lipids. As a general rule, these cationic lipids forming SLNPs often consist of 
amino lipids with ionizable amine headgroups and one hydrophobic part containing 
generally a double-hydrocarbonated alkyl chain. Designing and synthesizing 
combinatorial libraries of modified cationic lipids has become the main objectives of 
research groups in order to improve the potency of formulations in RNA interference 
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and antisense technology [31]. One of the main properties of SLNPs to take into 
account is the dissociation constant (pKa) of ionizable lipids since it can play an 
important role in both the ability to encapsulate nucleic acids and the promotion of in 
vitro and/or in vivo deliveries. By optimizing the design of SLNPs including the number 
of lipid-chain unsaturations, cationic head and linker chemistry, it could be estimated 
which dissociation constants would be optimal for nucleic acid delivery [32, 33]. 
The general structure for cationic lipids proposed by Alnylam Pharmaceuticals and 
Merck is shown in Figure 4B [34, 35]. These lipids are formed by a cationic head group, 
a linker, two hydrophobic alkyl chains and, finally, two bio-cleavable moieties 
containing hydrophobic chains as well. Representative cationic lipid derivatives 
synthesized by Alnylam are displayed in Figure 4B (compounds 7 - 10). Test 
formulations containing 7 – 10 along with a mixture of 1,2-distearoyl-sn-glycerol-3-
phosphocholine (DSPC), cholesterol (Chol) and PEG-lipid at their optimal molar ratios 
were able to encapsulate efficiently siRNA molecules in well-established protocols. The 
efficacy of SLNPs to impart cellular uptake and silence FVII mRNA were determined 
by a simple and plate-based colorimetric assay. The use of these formulations in vivo 
containing lipids (7 – 10) showed high levels of effectiveness compared to control 
animals with values of ED50 << 0.1 mg/kg.  
Other cationic lipids were published [36-38]. The synthesis of cationic lipids libraries 
containing two hydrocarbonated alkyl chains; in which the first one contained a long 
unsaturated hydrophobic moiety with double bonds and the second one was formed by a 
short saturated alkyl chain was reported. Biodegradable groups like esters (saturated and 
unsaturated) and different cationic heads [36-38] were successfully introduced. A 
selection of cationic lipid derivatives is displayed in Figure 4B (compounds 11 – 14). 
 11 
SiRNAs were encapsulated by impinging jet processes and the corresponding test 
formulations were evaluated to reduce ApoB levels in vivo. 
The alkylation reaction with epiclorhidrin and subsequent epoxide opening either with 
Grignard additions or alcohol residues afforded a novel family of cationic lipids 
containing both ether and diether-based alkyl residues, respectively. Representative 
compounds are displayed in Figure 4B (compounds 15 and 16) [39, 40]. Additionally, 
one of the cationic lipid alkyl chains could also be further functionalized with 
cholesterol. This modification allowed the preparation of amino derivatives containing 
different cationic heads and cholesterol residues (compounds 17 and 18) [41]. SLNPs 
containing cationic lipids 17 and 18 were evaluated for in vivo efficacy in a luciferase 
mouse model in order to silence ApoB mRNA in vivo. 
Other cationic lipids have been recently synthesized by Merck [42, 43]. The most 
representative ones are the cyclic amine 19 and 20, respectively (Figure 4C). After 
studying luciferase activity in vivo, a greater efficacy was observed in both cases 
reducing the luciferase expression in a dose-response manner. The evaluation of the 
toxicity and the efficacy of these two formulations to reduce in vivo ApoB was also 
accomplished obtaining an improved tolerability in rats compared to other formulation 
controls.  
Besides using ionizable lipids, guanidinium-based cholesterol derivatives (21 and 22, 
Figure 4C) described to deliver siRNA molecules [44]. It is well-known that having 
guanidinium groups (pK between 13 and 14) helps to compact zwitter ionic structures 
with negatively charged phosphate groups of nucleic acids. Thus, cationic lipids 21 and 
22 containing cholesterol and arginine moieties were encapsulated into SLNPs and 
evaluated in both in vitro and in vivo targeting human ErbB3 mRNA in cancer cells and 
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evaluating the down-regulation in human colon cancer in xenografted mice models, 
respectively.  
Cholesterol has also been introduced into other kinds of constructs. The synthesis and 
applications of a cationic carbamate series containing several cholesterol and 
hydrocarbonated alkyl residues covalently conjugated to N6-tetrakis-(3’-aminopropyl)-
1,3-propanediamine unit as a core structure has been published [45]. Some cationic 
carbamates are displayed in Figure 4C. Optimal formulations were produced by mixing 
cationic lipids (23 – 26) with phospholipids, polyethylenglycol derivatives and a sterol, 
preferably cholesterol. Two optimal formulations containing the cationic carbamate 26 
were used for liver siRNA delivery which reduced ApoB levels in vivo at a dosage of 
0.5-4 mg siRNA/Kg and lung siRNA delivery with promising results as well.  
Finally, Dicerna pharmaceuticals [46] developed a formulation strategy that combines 
polypeptide 27 containing Gly-(Arg-His)5 residues with several palmitoyl derivatives 
such as l-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (AzPC) and 1-palmitoyl-2-
glutaryl-sn-glycero-3-phosphocholine (GIPC) cationic lipids (Figure 4C). The synthetic 
strategy based on the conjugation of lysophosphatidyl choline with the two selected 
dicarboxylic acids of different length allowed the incorporation of the cationic 
polypeptide sequence separated by two ethylene glycol moieties obtaining either 
cleavable (28) or stable (29) constructs. The efficiency of these formulations containing 
these novel cationic lipids was demonstrated both in vitro and in vivo by reducing the 
expression of a target gene in an orthotopic animal tumor model. 
  
3.2 Lipid-oligonucleotide conjugates 
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As an alternative to the use of formulations obtained through electrostatic interactions, 
the introduction of covalent bonds between neutral or cationic lipids and nucleic acids 
represents an attractive approach to improve both the cellular uptake and the stability 
properties of nucleic acids. 
The introduction of cholesterol in the 3’-termini of a siRNA was the first example of 
this approach to silence apoB in liver and jejunum [47]. This approach has allowed the 
publication of patent applications and research articles covering covalent strategies to 
introduce lipophilic moieties at polynucleotides. In all cases, modifications containing 
two hydroxyl groups clearly differentiated, along with spacers of different length, are 
the preferred strategies to obtain nucleic acids modified with lipophilic moieties in a 
covalent manner.  
The synthesis of several oligonucleotide cholesterol type conjugates introduced at the 
5’- and/or 3’-end through several hydrocarbon or ether-linked moieties comprising 6 
and 10 carbons of length (Table 2) has been recently described by miRagen [48]. These 
conjugates were designed to mimic or target miR-208, which is a family of miRNA 
precursors that are specifically expressed in cardiac tissues obtaining good gene 
knockdown activities of miR-208.  
Other lipophilic moieties have been effectively introduced to modify siRNA molecules 
at both 3’- and 5’-termini [49, 50]. Sylentis SAU introduced sphingosine modifying 
siRNA molecules with 30 and 31. They observed that siRNA-sphingosine conjugates 
(Figure 5A) were able to silence EGFP expression showing an improved stability 
without affecting the efficacy of naked siRNAs in vitro [49]. Furthermore, a series of 
siRNA conjugates (33a-e) containing neutral and cationic lipids covalently linked at 
their 3’- and 5’-termini has also been described [50]. The authors observed that lipid 
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modifications did not affect the RISC machinery when lipid-siRNA conjugates were 
transfected in the presence of lipofectamine thereby obtaining similar inhibition 
activities than unmodified siRNA targeting TNF-α gene. Promising results were 
achieved when the lipid-siRNA conjugate 35, modified with two hydrocarbonated alkyl 
chains, efficiently silenced TNF-α expression in around 50% in the absence of 
commercially available cationic lipids [50].  
Other strategies used for the delivery of siRNA molecules have been published [51]. 
These constructs are based on a cholesterol molecule covalently linked through amide 
bonds to alkyl or pegylated spacers and a dipeptide having phenylalanine (Phe) and 
lysine (Lys) residues. Additionally, the general structure can contain a cleavable p-
aminobenzylcarbamate spacer and a siRNA binding site, which has a p-nitrophenyl 
activated carbonated moiety (36, Figure 5C). Therefore, modified amino siRNAs can be 
efficiently conjugated to the cholesterol-di-peptide structure by the nucleophilic 
displacement of p-nitrophenyl moiety thereby obtaining the corresponding carbamate 
molecule 37. When these kinds of cholesterol-siRNA conjugates are taken up by cells, 
an expected 1,6-elimination reaction is produced, thus inducing the release of the 
siRNAs by lysosomal degradation inhibiting gene expression of a target mRNA. This 
patent application describes the ability of these siRNA conjugates containing Phe-Lys 
dipeptides to impart cellular uptake reducing ApoB levels in both in vitro and in vivo 
assays. SiRNA conjugates containing cleavable linkers showed better gene knockdown 
efficiencies than non-cleavable cholesterol siRNA conjugates. The authors also 
confirmed that the original Phe-Lys motifs present in cholesterol di-peptide siRNA 
conjugates were strictly necessary to decrease the production of ApoB so that the same 
siRNA conjugates containing other dipeptide motifs obtained less activity efficiencies 
in silencing ApoB. Finally, Phe-Lys dipeptide-siRNA conjugates 38 containing both 
 15 
cholesterol and N-acetyl-D-galactosamine ligands were covalently linked. Carbohydrate 
ligands increased the efficacy of these conjugates in cellular uptake processes through 
receptor-mediated endocytosis due to their high binding affinities for the 
asialoglycoprotein receptor (ASGPR).  
3.3 Peptides. 
Peptides have emerged as a new class of non-viral vectors allowing the delivery of 
various drugs including nucleic acids through a mechanism of internalization that is still 
controversial and depends on the nature of the peptide. Cell penetrating peptides (CPP) 
also named protein transduction domains, comprise short and usually basic amino-rich 
peptides originating from proteins able to cross cellular membranes. Several groups 
have published patent applications covering delivery molecules formed by different 
polypeptides that are bound to nucleic acids by conjugation or by a non-covalent 
approach via electrostatic interactions. Polypeptide delivery systems are different 
peptide combinations containing one or several peptides related to extracellular receptor 
proteins of targeted cells, peptides that enhance the delivery or interact with nucleic 
acids. These systems form stable complexes with nucleic acids in the presence of serum 
and sometimes are able to escape from endosomal-lysosomal compartment.  
 
3.3.1 Non covalent approach. Chimera cell delivery peptides comprising a positively 
charged peptide and a targeting-delivery peptide are capable of highly efficient delivery 
of nucleic acids into cardiac and skeletal muscle cells. Therefore the constructs may be 
used for treatment of a cardiac or skeletal muscle diseases or muscular dystrophy [52]. 
The targeting-delivery peptide is selected from MSP (muscle-specific protein) or from 
reported peptides to transfect antisense PNA (peptide nucleic acid) or PMO 
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(phosphorodiamidate morpholino oligonucleotide) to skeletal muscle with high 
efficiency.  
In a similar system, the carrier is composed of three main peptide segments, a unit 
designed to bind to specific target cells, a unit designed to mediate penetration into the 
interior of target cells and a unit that can interact with nucleic acids designed to mediate 
RNAi. The complexes (peptide/ siRNA) are formed by combining the 'Her' domain for 
binding heregulin receptors of breast cancer cells and peptides derived from 
recombinant adenovirus (Ad) capsid protein. Finally, binding and transport of nucleic 
acids can be mediated by the polylysine, 'KlO' domain [53].These carriers also protects 
the siRNA from serum nucleases.  
Synthetic peptides including apolipoprotein E (ApoE) which are believed to bind with 
various proteins (albumin and/or immunoglobulins) that are presumably recognized by 
the low-density lipoprotein receptor (LDLR) pathway are able to cross the blood-brain 
barrier (BBB) through transcytosis [54]. Peptide constructs to deliver nucleic acids 
comprise a mixed sequence of hydrophilic amino acids and a blood-brain barrier agent 
derived from the receptor binding domain of an apolipoprotein. 
Another interesting invention relates the use of combination of anti-cadherin 
oligonucleotides to one or more other anti-cadherin agents including peptides that bind 
cadherin extracellular domains useful in the treatment of acute, delayed healing and 
chronic wound [55]. Similarly, chimeric RNA linked to a polypeptide moiety is able to 
reduce DNA methylation. The RNA oligonucleotide also includes a therapeutic agent 
selected from a demethylating agent (e.g., 5-azacytidine (azacitidine), 5-aza-2'-
deoxycytidine (decitabine)) to enhance binding to DNA methyltransferases (DNMT) 
[56]. 
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Antimicrobial compositions including a CPP is combined with or conjugated to a 
functional nucleic acid (including morpholino oligonucleotides), such as an external 
guide sequence (EGS) which can target and reduce expression of essential microbial 
genes or genes than impart resistance to antimicrobial drugs [57]. Likewise, different 
polypeptides moieties containing at least one of thymosin, any interferon or pegylated 
derivative, myrcludex B or any antiviral cytokine or pegylated derivative have been 
used to enhance the delivery of antiviral oligonucleotide chelates [58]. 
Another strategy for improving the delivery and stability of therapeutic 
oligonucleotides, named NickFect, relates to chemically modified new branched CPP 
with fatty acids attached to a targeting moiety that is capable of reaching specific cells 
or tissues of interest. The targeting moiety may be an aptamer or a targeting peptide, 
such as a homing peptide or a receptor ligand [59]. 
 
3.3.2 Covalent approach. The main drawbacks of using CPP not covalently linked to 
nucleic acids are their potential toxicity and the endosomal entrapment [60]. Linking 
CCP to oligonucleotides leads to well-defined, single-component systems that use only 
equimolar ratios of the delivery material and nucleic acid.  
Several groups describe different constructs based on directed attachment to nucleic 
acids. One strategy is the preparation of amino functionalized oligonucleotides that are 
transformed to maleimido-oligonucleotides. These are able to react with modified 
cysteine forming a maleimido-thiol covalent bonds [61]. These therapeutic conjugates 
contain a peptide that specifically homes to endothelial cells in the tumour for the 
efficient delivery of sequence-specific antisense to cells of a selected type.  
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By linking a cell-penetrating peptide to a substantially uncharged antisense nucleic acid 
analogue via a glycine or proline amino acid, the resulting conjugates decreased the 
toxicity and/or enhanced cell delivery, potency, and/or tissue distribution [62]. 
Another approach consists of preparing peptide segments that are useful for facilitating 
the uptake across cell membranes, the segments are separated by aminohexanoic spacer 
residues and may also include non-natural amino acids [63]. Both PMO and PNA 
antisense are conjugated at the C-terminus of the peptide and are able to modulate 
dystrophin pre- mRNA splicing, thereby specifically restoring the dystrophin reading 
frame and generating a truncated but semi-functional dystrophin protein.  
Modified and derivatised CPP with fatty acid conjugated to nucleic acids have been 
used to enhance transfection with less toxicity for splice correction as well as siRNA 
delivery [64]. Additionally, the system comprises irreversibly chloroquine-coupled 
compounds for endosomal escape.  
Maurocalcine is the first demonstrated example of an animal toxin peptide with efficient 
cell penetration properties. The toxin is a 33-amino acid peptide and the invention 
relates to small CPPs derived from this toxin and to their use as vectors for the 
intracellular delivery of various drugs and agents [65]. The peptide is derivatized and 
coupled to oligonucleotides via a disulphide bond, thioether, thiol-maleimide or amide 
linkage. Other methods of linking the peptide to the oligonucleotide include the use of a 
C-terminal aldehyde to form an oxime, the use of a click reaction or the formation of a 
morpholino linkage with a basic amino acid on the peptide. 
Formulations containing phase changing charge-trapped peptides and nucleic acids have 
been optimized to increase cellular uptake and cytoplasmatic delivery of 
oligonucleotides [66]. Some of these changes includes pH change induced 
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protonation/deprotonation, disulphide reduction, hydrolysis and proteolysis. The 
process involves designing candidate-phase changing, charge-trapped peptides, 
including designing amino acid consensus sequences with phase changing charge- 
trapped residues, providing a library of such peptides and screening the peptides for 
their efficacy in knocking down the cellular expression of a target gene.  
Another invention relates to the use of a carrier peptide system that is designed to 
harness and/or exploit fully natural pathways for initial cell targeting and 
internalization, followed by retrograde transport through membranous compartments to 
the endoplasmic reticulum (ER) and retro-translocation from the ER to the cytosol via 
the ER-associated degradation pathway (ERAD) [67]. Specifically, the delivery system 
comprises several modules linked by cysteine side chain as branch point. One module 
mediates cell targeting and facilitates cellular uptake, whereas the other facilitates 
transport to the ER. The last one mediates translocation from the ER to the cytosol. 
 
3.4 Small-molecule ligands 
 
3.4.1 Small-molecule ligands for receptor mediated uptake. A number of promising 
small organic ligands have been developed to improve the delivery of nucleic acids by 
direct conjugation. These bioactive molecules have very diverse structures and are 
linked to nucleic acids through different bonds. 
Vitamins have been conjugated to nucleic acids. In this context, α-tocopherol has been 
linked to nucleic acids such as siRNA providing a method for suppressing a target gene 
expression (apoB) in vivo more safely and efficiently [68]. Alternatively, α-tocopherol-
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bound nucleic acids were mixed with extracted chylomiclon, and then administered. 
Multivitamin B12 conjugates for RNAi therapeutics can assist in one or more of cell 
targeting, and/or the release the oligonucleotide or oligonucleotide conjugate into the 
cell cytoplasm [69]. The above conjugate can be formulated to provide some protection 
from degradation or denaturing of the oligonucleotide. The delivery systems also 
comprise nanoparticles which may assist cell targeting. Folic acid has been also 
conjugated to nucleic acids. Folate conjugates can enter cells by receptor- mediated 
endocytosis. Folate siRNA using different linkers targets tumors or cells of the immune 
system overexpressing folate receptors and causing cancer, or inflammatory diseases, 
respectively [70]. 
Other small molecules such as selected alkyl or heteroaromatic [71] or minor groove 
binders [72] have been attached to siRNA in order to improve cell penetration and 
biodistribution properties. 
In addition, small organic ligands for a membrane-bound protein are covalently coupled 
to an oligonucleotide [73]. The ligand is coupled through a linking group that comprises 
a phosphate group covalently coupled to an aliphatic or an aliphatic oxide group. 
Ligands are designed for membrane-bound proteins, such as G-protein, or several 
receptors such as ion-channel receptors, tyrosine kinase-linked receptors, receptor 
tyrosine kinases, cytokine receptors, and receptors with intrinsic enzymatic activity. 
One of the most clinically advanced conjugate is the N-acetylgalactosamine (GalNAc) 
conjugate by Alnylam Pharmaceutical. A triantennary system with optimized spacer-
linked GalNAc molecules is designed to achieve targeted delivery of RNAi therapeutics 
to hepatocytes through uptake by the asialoglycoprotein receptor with high affinity. 
These constructs have effective delivery efficiency, as well as efficient cellular uptake 
 21 
and/or endosomal escape properties. Improved knockdown of the target gene was 
obtained by subcutaneous administration. No evidence of cytokine induction, 
complement activation or other adverse effects was observed using a wide therapeutic 
window. N-acetylgalactosamine-conjugated melittin-like peptide platform with potent 
cholesterol-siRNA targeting hepatitis B virus resulted in a good in vivo therapeutic 
treatment without changes in cytokines [74]. 
A siRNA conjugate targeting the Transthyretin (TTR) gene was described for the 
treatment of TTR-mediated amyloidosis [75]. Similarly, a modular composition 
comprising the tetraGalNAc ligands attached to the passenger strand of siRNA at 
different 2'-positions of the ribose rings and/or at different terminal 3' and/or 5'-
positions were described. These systems allow the addition of other targeting ligands 
such as solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking 
agents [76]. Asialoglycoprotein and folate receptors were also targeted by a galactose 
cluster-pharmacokinetic modulator moiety (siRNA-conjugate) with in vivo circulating 
and targeting properties compared to the targeting ligand alone. The pharmacokinetic 
modulator comprises a hydrophobic group. The delivery system also comprises a 
polyamine polymer not conjugated to siRNA [77]. 
The incorporation of a non-ionic, low-osmolar contrast agent to antisense 
oligonucleotides is described for treating a neurodegenerative disease [78]. These 
contrast agents such as iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, 
ioversol or ioxilan are able to cross the blood-brain-barrier and to be delivered to any 
tissue throughout the body, particularly the entire nervous system; this includes both the 
and the peripheral nervous system. Antisense oligonucleotides can bind to a survival 
motor neuron (SMN) gene or other related genes. In addition, morpholino antisense 
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oligonucleotides can bind CAG repeats, CTG repeats, CCTG repeats, or GGGCC 
repeats. 
Targeted delivery of siRNA is accomplished by the the conjugation of 5'-thio-siRNA 
with selective small molecule alpha-V-beta-3 [79] or LFA-1 [80] VLA-4 [81] integrin 
antagonists containing appropriate linkers (e.g. ethyleneglycol) and functional groups 
(e.g. maleimido). Moreover, the conjugation of oligonucleotides with intracellular 
retrograde transport inhibitors (retro compound) such as an imine derivative or a 
benzodiazepine derivative increases the delivery and/or the activity of the 
oligonucleotide in the cell [82]. 
 
3.4.2 Multiplex structures. The delivery system called QFect for intracellular cargo 
delivery comprise a multicomponent system containing quinoline or naphthalene 
compound, an aliphatic linear or branched hydrophobic chain and an optional targeting 
moiety, such as homing peptide or an aptamer [83]. 
Another multiplexed structure invention to enhance oligonucleotide delivery comprises 
a modular composition. Specifically, an oligonucleotide (siRNA) with one or more 
linkers attached at any 3' and/or 5' end and one or more peptides attached to the linkers 
and optionally lipids, solubilizing groups and/or targeting ligands [84]. 
 
3.4.3 Aptamers. Targeted aptamers can be used as vehicles to deliver specific agents to 
particular sites. Alternatively, targeted aptamers can also be used along detection 
techniques to determine either the presence or the absence of specific targets in 
heterogeneous backgrounds.  
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Chimeric molecules such as aptamer-oligonucleotide conjugate have been described to 
improve the delivery and inhibition of the conjugated to specific cells. Specifically, a 
prostate-specific membrane antigen (PSMA) aptamer is conjugated to siRNA in order to 
inhibit nonsense-mediated mRNA decay (NMD), a surveillance mechanism which 
prevents the expression of mRNAs containing a premature termination codon [85]. 
New aptamers are developed to target tumor-associated antigen (CEA) [86]. Aptamers 
have been also used to release a specific drug. This is the case of an aptamer/insulin 
conjugate complex from which insulin may be released by an innocuous, orally 
administrable trigger, such as quinine [87]. 
 
3.5 Polysaccarides and other natural polymers 
Chitosans, glucan, dextrans and glucosamines are usually used as a delivery vehicle of 
therapeutic nucleic acids. These compounds may provide some advantages, including 
efficient transfection, bio-delivery, and availability, buffering ability or serum stability. 
Modified chitosan with one secondary or tertiary amine are able to introduce imidazole 
groups [88]. Other approaches include chitosan-arginine, chitosan-lysine and chitosan-
histidine modifications [89].  
Additionaly, hydrophobic modified polynucleotide complexed with a glucan-containing 
particle have significantly reduced toxicity, are better recognized by phagocytic cells, 
and have a more efficient payload release and overall efficacy [90].  
Several nanoparticle compositions containing chitosan have been described to improve 
nucleic acids delivery. A composition of a water-soluble chitosan, a thiamine 
pyrophosphate, a protamine, and a neutral or anionic phospholipid exhibits biostable 
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nanoparticle properties. This improved chitosan composition prevents aggregation of 
the chitosan with serum proteins [91]. Similarly, modified nanoparticle chitosan with a 
biocompatible layer that comprises poly(L-histidine) or a chelating agent moiety has 
been used for a divalent metal transporter of an olfactory nerve terminal. This method 
comprises nucleic acid delivery to the central nervous system [92]. 
Cyclodextrins are a group of cyclic polysaccharides comprising six to eight naturally 
occurring D(+)-glucopyranose units in alpha-(1,4) linkage. Modified forms of 
cyclodextrin with cationic arms covalently bound form well defined stoichiometric 
complexes with nucleic acids (siRNA) [93]. 
 
3.6 Synthetic polymers 
A large number of polymeric systems have been developed for drug delivery [94]. Most 
of the polymeric systems have been developed for the delivery of small therapeutic 
molecules decreasing toxicity by slow degradation of polymer and / or release of the 
drugs in cellular conditions. 
Cationic polymers such as polyethyleneimine (PEI) were one of the first polymers used 
for oligonucleotide delivery, since the acidic pH of the endosomes trigger the liberation 
of the cargo in the cytoplasm. Recently, new PEI derivatives carrying several 
ethylcarbamoylphenyl side chains have been proposed for siRNA delivery to decrease 
undesired toxicity [95]. Moreover, polypropyleneimine (PPI) has been described to 
deliver siRNA [96].  
In a recent development a large number of polymers and conjugates have been 
described for delivering nucleic acids [97]. These systems include polyacrylates, 
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polylactides, polyesters and polyvinyl derivatives, as well as hydrophilic-hydrophobic 
copolymers such as polylactic-glycolic acid (PLGA), polyethyleneglycol-PLGA and 
others. Surprisingly, negatively charged polymers as well as amphiphilic polymers have 
demonstrated improved silencing efficiency and reduction of cell toxicity when used to 
deliver morpholino (PMO) and PNA oligomers [98]. PLGA microparticles have been 
described for the encapsulation of triplex-forming PNAs [99]. 
Specifically biodegradable polymeric made of poly(lactic) copolymerized with several 
hydrophilic-hydrophobic polymers such as polymetacrylic acid or poly(ethyleneglycol), 
or polystyrene, or poly(vinylpyridine) and more have been developed [100]. The main 
effect of the copolymers is the possibility of tuning up different degradabilities of the 
polymers depending on the amount of copolymer without compromising the low 
toxicity of poly(lactic) polymer [101].  
Polyamides derived from diaminopropane derivatives [102], ornithine [103] or 
ornithine-phenylalanine [104] carrying protonable amine groups as side chains have 
been described as membrane lytic polymers for delivery of siRNA. Oligonucleotides as 
well as polyethyleneglycol and N-acetylgalactosamine molecules for cell targeting are 
conjugated to amino side chains. 
Dynamic polyconjugates (DPC) made of polyvinylether copolymers with several side 
chains for controlling functionalization and biodegradability are probably one of the 
most exciting solutions for nucleic acid delivery [105]. The use of reversible linkages 
connecting the different components of the delivery system provides physiologically 
modulation of the release of the components [105]. Modified polyacetal derivatives 
resulting from the oxidation of polydextranes have been efficiently loaded with nucleic 
acids and several targeting groups with good biodegradability properties [106]  
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The combination of graft copolymers of polyacrylic acid with cationic lipids has been 
described [107]. Electrostatic interaction between polyacrylic polymers direct the 
binding of cationic lipids and this combination can be used for the delivery of plasmid 
DNA, antisense oligonucleotides and siRNA [107]. The use of ionic monomers such as 
dimethyloctylammonium acrylate derivatives in the polymerization of methyl 
methacrylate has been described for the preparation of core-shell polymers complexes 
with oligonucleotides designed for restoring the expression of the dystrophin protein by 
exon skipping mechanism [108]. Moreover, functionalization of polymers derived from 
dimethylacrylic acid with siRNA and ligands to facilitate endosomal escape has been 
developed [109]. 
 
3.7 Nanomaterials 
The rapidly expanding field of nanotechnology has allowed the synthesis of well 
defined nanoparticles (NPs) of diverse materials. These NPs can be functionalized either 
with positive charges to condense DNA or RNA molecules or with therapeutic 
oligonucleotide sequences such as antisense, siRNA or aptamers. The functionalized 
biocompatible nanomaterials, such as gold, silica, iron oxide, carbon nanotubes or 
graphene oxide, have been used for the delivery of oligonucleotides [4].  
The ability of oligonucleotide-NP conjugates, especially gold NPs, to penetrate a wide 
variety of cell types has been used to provide new delivery systems for therapeutic 
agents such as alkylating agents, DNA intercalating agents, antimetabolites or proteins 
of interest [110-112]. In order to avoid the large uptake of gold NPs from the 
reticuloendothelial system, the addition of an embolic agent such as lipid emulsions or 
biodegradable microspheres has been proposed [113].  
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Recently, gold nanoparticles have been used as a template for the preparation of hollow 
silica particles that can be functionalized with therapeutic oligonucleotide sequences 
with high load and low toxicity [114]. The coating of mesoporous silica NPs with 
cationic polymers has also been described as a suitable carrier for siRNA transfection 
[115]. 
Carbon nanotubes have also been developed for drug delivery. In a recent description 
single wall carbon nanotubes functionalized with morpholino oligonucleotides are 
prepared in order to form two-component self-assembling units that allow the efficient 
delivery of the active morpholino oligonucleotides inside of tumor cells [116]. Carbon 
nanotubes can be functionalized with cationic compounds such as polylysine, cationic 
lipids, dendrimers for targeted delivery of therapeutic oligonucleotides to specific cell 
types to reduce cellular toxicity [117]. 
 
4. Expert opinion 
Cellular delivery of nucleic acids requires the combination of two factors: cellular 
penetration and escape from endosomal compartments. Much progress has been made in 
the last years in understanding these issues, which are crucial for the efficacy of 
therapeutic oligonucleotides. Cationic lipids are the most used vehicles for the 
preparation of novel formulations as they are the simplest and the fastest way to bind 
non-viral vectors with nucleic acids taking advantage of the electrostatic interactions. 
Solid lipid nanoparticles carrying synthetic cationic lipids, cholesterol and 
polyethyleneglycol have emerged as a winning alternative to liposomes. Combinatorial 
libraries of cationic lipids have been used for the screening and development of cationic 
lipids with enhanced cellular uptake and biocompatibility. Significant developments 
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from Alnylam Pharmaceuticals, Merck Sharp & Dohme, Dicerna pharmaceuticals and 
Agave Pharma in searching new cationic lipids have led to the successful delivery of 
oligonucleotides to liver and lung tissues.  
The synthesis of an oligonucleotide covalently-linked to lipids has emerged as a 
promising alternative to the use of formulations. The introduction of covalent links to 
neutral lipids such as cholesterol (miRagen Therapeutics), sphingosine (Sylentis) or 
cationic lipids into nucleic acids represents an attractive approach to improve both the 
cellular uptake and stability properties of nucleic acids. The use of peptides as cleavable 
spacers between cholesterol and the oligonucleotide moieties (Hoffmann-LaRoche) 
adds a very interesting novelty for lysosomal degradation that generates better silencing 
efficiencies.  
The use of peptides as non-viral vectors instead or in combination with lipids is also an 
expanding field for oligonucleotide delivery. This strategy is certainly advantageous for 
delivering non-charged nucleic acids derivatives such as PNA and PMO derivatives 
showing interesting results in the treatment of muscular dystrophy by exon skipping. 
The covalent linking of peptides to oligonucleotides seems promising given to the use 
of several peptides with different functions but in fact it did not provide until now 
interesting results until now, except in the already mentioned delivery of PNA and PMO 
derivatives.  
The introduction of small molecule ligands into oligonucleotides in order to increase 
cellular uptake by receptor-mediated endocytosis has been also pursued with relatively 
good results in the case of the use of N-acetylgalactosamine conjugates that provide 
good uptake to hepatocites by the asialoglycoprotein receptor. These conjugates are 
currently under clinical evaluation. 
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Synthetic and natural polymers may also play an important role in the forthcoming 
years. The large development in the last years directed to the delivery of small 
therapeutic drugs has provided good technological polymeric platforms in terms of nice 
cellular uptake, good biodegradability, good biocompatibility, and the possibility to 
incorporate several components such as ligands for receptor mediated endocytosis and 
molecules to facilitate endosomal escape. Low functionalization, toxicity and batch-to-
batch reproducibility are still the potential negative outcomes that will be solved in the 
coming years with the most advanced polymers chitosans, dextrins, PLA, PLGA and 
PEI derivatives. 
Finally, the use of nanomaterials has opened a new avenue for oligonucleotide delivery 
with similar advantages and disadvantages described for polymeric delivery systems. In 
our opinion, silica and gold nanoparticles have the best options to provide efficient 
functionalization and good cellular uptake properties. Recent results with graphene 
oxide functionalized with cationic molecules may also be an interesting alternative.  
The use of nucleic acids for inhibiting the expression of target genes at the level of 
mRNA has obtained, in most cases, excellent results in vitro. However, the therapeutic 
applications of oligonucleotides in vivo have undergone multiple obstacles, such as 
stability and cellular internalization. Immunogenicity and cytotoxicity are other issues 
to take into account. These hurdles clearly reduce the possibilities of success for these 
therapies although some proof-of-principle studies have demonstrated promising 
silencing activities without secondary effects. The development of safe and efficient 
delivery systems continues to be challenging, but the last developments showed 
improved in vivo efficacy, thus gaining a foothold in therapeutics. 
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Figure 1. Chemical modifications carried out to improve the stability of oligonucleotides 
 
Unmodified
O
OHO
P O
O
O
O
Base
FO
PO
O
O
O
O Base
O
PO
O
O
O
O Base
OMe O
PO
O
O
O
O Base
OCH2CH2OMe
O
O
O
PO
O
S
OH
Base
OHO
P
O
O
O
O Base
BH3
OHHN
P
O
OO
O
O Base
N
O
O
P
O
O
Base
NMe2 NHO
N
O
Base
PhosphoramidateBoranophosphatePhosphorothioathe
Modifications on the phosphate backbone
PNAMorpholino
Modifications on phosphate group
2'-O-Methyl2'-FluoroPhosphodiester
Modifications on sugar ring
LNA2'-O-Methoxyethyl
- - - -
- -
O
O
O
O
PO
O
O
Base
6'-Me-LNA
-
O Base
O
OO
P O
O
O
-
 
 
 45 
Table 1. Antisense and siRNA oligonucleotides in the clinical pipeline 
Drug Carrier Target Disease Phase Company Status* 
Macugen RNA aptamer VEGF 
Age-related macular 
degeneration III Pfizer approved 
Mipomersen ASO ApoB Hypercholesterolaemia III ISIS approved  
Oblimersen ASO Bcl2 cancer II Genta completed (NCT00064259) 
Custirsen ASO Clusterin Prostate cancer III OncoGenex ongoing (NCT01578655) 
IMO-2055 ASO TLR9 Renal cell carcinoma II Idera Pharmaceuticals 
completed 
(NCT00729053) 
PF04523655 siRNA RTP801/REDD1 Wet AMD and DME II Quark Pharmaceuticals 
completed 
(NCT01445899) 
Excellair siRNA SYK kinase Asthma II ZaBeCor ongoing 
TD101 siRNA Keratin 6a (N171 mutation) Pachyonychia Congenita Ib TransDerm 
completed 
(NCT00716014) 
AGN211745 siRNA VEGFRI Age-related macular degeneration II Allergan 
completed 
(NCT00395057) 
ISIS-
STAT3Rx ASO STAT3 DLBCL limphoma I/II Isis 
Pharmaceuticals 
ongoing 
(NCT01563302) 
ISIS-
PTP1BRx ASO PTP-1B Type 2 Diabetes II 
ongoing 
(NCT01918865) 
Eteplirsen 
(AVI-4658) PMO Exon 5 
Duchenne muscular 
dystrophy II 
Sarepta 
Therapeutics 
completed 
(NCT01396239) 
Bevasiranib siRNA VEGF 
 
AMD III Opko Health, Inc completed (NCT00499590) 
ALN-VSP02 siRNA Solid tumors I Alnylam Pharmaceuticals 
completed 
(NCT01158079) 
Sirna-027 siRNA AMD Age-related macular degeneration I/II 
Allergan/Sirna 
Therapeutics 
completed 
(NCT00363714) 
SYL040012 siRNA ADRB2 Ocular hypertension I/II  
Sylentis 
completed 
(NCT01227291) 
SYL1001 siRNA TRPV1 Dry eye I/II ongoing (NCT01776658) 
CALAA-01 siRNA RRM2 Solid tumor cancers I Calando Pharmaceuticals 
completed 
(NCT00689065) 
ALN-TTRSC siRNA 
TTR TTR cardiac amyloidosis 
II 
Alnylam 
Pharmaceuticals 
ongoing 
(NCT01981837) 
ALN-TTR02 siRNA II ongoing (NCT01617967) 
ALN-RSV01 siRNA RSV RSV infection IIb completed (NCT01065935) 
ALN-PCS02 siRNA PCSK9 Hypercholesterolemia I completed (NCT01437059) 
TKM-080301 siRNA PLK1 Advanced solid tumors II Tekmira Pharmaceuticals 
ongoing 
(NCT01262235) 
SPC2996 LNA PS Bcl2 Chronic lymphocytic leukemia I/II Santaris Pharma 
completed 
(NCT00285103) 
Atu027-I-02 siRNA PKN3 Metastatic pancreatic cancer I/II 
Silence 
Therapeutics 
ongoing 
(NCT01808638) 
RXI-109 siRNA CTGF Hypertrophic scar II RXi Pharmaceuticals 
ongoing 
(NCT02030275) 
CRLX-101 siRNA Topoisomerase I Rectal cancer II Cerulean Pharma ongoing (NCT02010567) 
QPI-1002 siRNA P53 ischemia-reperfusion-related injuries I/II 
Quark 
Pharmaceuticals 
ongoing 
(NCT00802347) 
*http://www.clinicaltrials.gov 
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Figure 2. Strategies to deliver nucleic acids (cargo) by using non-viral carriers: A. Formulation 
and B. Covalent approaches. 
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Figure 3. Some of mechanisms used for the inhibition of gene expression implies antisense 
inhibition with the intervention of RNase H (A), RNA interference mechanism (B) or steric-
blocking of mRNA (C). 
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Figure 4. General structures of modified PEGylated lipids (A), representative ionizable cationic 
lipids containing biodegradable moieties (B) and other constructs (C) used in formulations. 
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Table 2. Potential sites of conjugation with cholesterol modifying mir-208 molecules at both 3’- 
and 5’-termini 
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Figure 5. Synthetic strategy to introduce sphingosine (A), neutral and cationic lipids (B) at both 
3’- and 5’-termini and other constructs (C) 
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C. Other constructs
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Cholesterol
Di-peptide motif with R1-(phenyl)alanine 
moiety and R2-lysine moiety
Conjugation site
enzymatic cleavage
nucleic acid
siRNA conjugate
Conjugation site
38
H H
H
where Y = -(CH2)3- or C(O)N-(CH2-CH2-O)n-CH2-CH2-
 
 
 
